Modified fatty acids and their possible therapeutic targets in malignant diseases

Expert Opinion on Therapeutic Targets

Volumn 7, Issue 5, 2003, Pages 663-677

  Tronstad, Karl J ^a   Berge, Kjetil ^a   Berge, Rolf Kristian ^a   Bruserud, Øystein ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Chemoprevention; Chemotherapy; Cyclooxygenase 2 (COX 2); Histone deacetylase (HDAC); Mitochondria; Modified fatty acids; Protein farnesylation; Retinoids

Indexed keywords

4 N ACETYLDINALINE; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ACETYL COENZYME A CARBOXYLASE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; BEXAROTENE; BUTYRIC ACID; CARDIOLIPIN; CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FATTY ACID DERIVATIVE; FATTY ACID SYNTHASE; FENRETINIDE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HORMONE RECEPTOR; HYDROXAMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RAS PROTEIN; RETINOIC ACID; RETINOID DERIVATIVE; RETINOL DERIVATIVE; TRICHOSTATIN A; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER PREVENTION; CANCER THERAPY; CELL FUNCTION; CELL GROWTH; CHEMICAL MODIFICATION; CLINICAL TRIAL; CONFUSION; DIET THERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; GENE FUNCTION; HEAD AND NECK CANCER; HUMAN; HYPOCALCEMIA; LIPID METABOLISM; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRION; MOUTH CANCER; NONHUMAN; PROMYELOCYTIC LEUKEMIA; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; SOMNOLENCE; T CELL LYMPHOMA; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; CYCLOOXYGENASE 2 INHIBITORS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; EICOSANOIDS; FATTY ACIDS; GENES, RAS; HISTONE DEACETYLASES; HUMANS; MITOCHONDRIA; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN ISOPRENYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 0141961576     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.7.5.663     Document Type: Review

References (122)

1. JOSEFSON D: Obesity and inactivity fuel global cancer epidemic. BMJ (2001) 322(7292):945.
2. PETO J: Cancer epidemiology in the last century and the next decade. Nature (2001) 411(6835):390-395.
3. PAUMEN MB, ISHIDA Y, MURAMATSU M, YAMAMOTO M, HONJO T: Inhibition of carnitine palmitoyltransferase I augments sphingolipid synthesis and palmitate-induced apoptosis. J. Biol. Chem. (1997) 272(6):3324-3329.
4. DE PABLO MA, SUSIN SA, JACOCOT E et al.: Palmitate induces apoptosis via a direct effect on mitochondria. Apoptosis (1999) 4:81-97.
5. SANTINI V, GOZZINI A, SCAPPINI B, GROSSI A, ROSSI FERRINI P: Searching for the magic bullet against cancer: the butyrate saga. Leuk. Lymphoma (2001) 42(3):275-289.
6. PARIZA MW, PARK Y, COOK ME: Conjugated linoleic acid and the control of cancer and obesity. Toxicol. Sci. (1999) 52(2 Suppl.): 107-110.
7. PINEAU T, HUDGINS WR, LIU L et al.: Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem. Pharmacol. (1996) 52(4):659-667.
8. SAMID D, RAM Z, HUDGINS WR et al.: Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res. (1994) 54(4):891-895.
9. HONG WK, LIPPMAN SM, ITRI LM et al.: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. (1990) 323(12):795-801.
10. LIPPMAN SM, KAVANAGH JJ, PAREDES-ESPINOZA M et al.: 13-cis-retinoic acid plus interferon α-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J. Natl. Cancer Inst. (1992) 84(4):241-245.
11. BRUSERUD O, GJERTSEN BT: New strategies for the treatment of acute myelogenous leukemia: differentiation induction - present use and future possibilities. Stem Cells (2000) 18(3):157-165.
12. JIANG WG, BRYCE RP, HORROBIN DF: Essential fatty acids: molecular and cellular basis of their anti-cancer action and clinical implications. Crit. Rev. Oncol. Hematol. (1998) 27(3):179-209.
13. KUMAR GS, DAS UN: Free radical-dependent suppression of growth of mouse myeloma cells by α-linolenic and eicosapentaenoic acids in vitro. Cancer Lett. (1995) 92(1):27-38.
14. SEBTI SM, TKALCEVIC GT, JANI JP: Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Cancer Commun. (1991) 3(5):141-147.
15. LENZ M, MIEHE WP, VAHRENWALD F, BRUCHELT G, SCHWEIZER P, GIRGERT R: Cholesterol based antineoplastic strategies. Anticancer Res. (1997) 17(2A):1143-1146.
16. OSTRANDER DB, SPARAGNA GC, AMOSCATO AA, MCMILLIN JB, DOWHAN W. Decreased cardiolipin synthesis corresponds with cytochrome c release in palmitate-induced cardiomyocyte apoptosis. J. Biol. Chem. (2001) 276(41):38061-38067.
17. ESPOSTI MD: Lipids, cardiolipin and apoptosis: a greasy licence to kill. Cell Death Differ. (2002) 9(3):234-236.
18. PALAKURTHI SS, FLUCKIGER R, AKTAS H et al.: Inhibition of translation initiation mediates the anticancer effect of the n-3 polyunsaturated fatty acid eicosapentaenoic acid. Cancer Res. (2000) 60(11):2919-2925.
19. DAS UN: Essential fatty acids, lipid peroxidation and apoptosis. Prostaglandins Leukot. Essent. Fatty Acids (1999) 61(3):157-163.
20. JENUWEIN T, ALLIS CD: Translating the histone code. Science (2001) 293(5532):1074-1080.
21. GRUNSTEIN M: Histone acetylation in chromatin structure and transcription. Nature (1997) 389(6649):349-352.
22. MARKS PA, RICHON VM, RIFKIND RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. (2000) 92(15):1210-1216.
23. MARKS P, RIFKIND RA, RICHON VM, BRESLOW R, MILLER T, KELLY WK: Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer (2001) 1(3):194-202.
24. RICHON VM, O'BRIEN JP: Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin. Cancer Res. (2002) 8(3):662-664.
25. KELLY WK, O'CONNOR OA, MARKS PA: Histone deacetylase inhibitors: from target to clinical trials. Expert Opin. Investig. Drugs (2002) 11(12):1695-1713.
26. VAN LINT C, EMILIANI S, VERDIN E: The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. (1996) 5(4-5):245-253.
27. KIM YB, LEE KH, SUGITA K, YOSHIDA M, HORINOUCHI S: Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene (1999) 18(15):2461-2470.
28. MATSUYAMA A, SHIMAZU T, SUMIDA Y et al.: In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. (2002) 21(24):6820-6831.
29. LIN RJ, NAGY L, INOUE S, SHAO W, MILLER WH Jr, EVANS RM: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 391(6669):811-814.
30. GRIGNANI F, DE MATTEIS S, NERVI C et al.: Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 391(6669):815-818.
31. GORE SD, CARDUCCI MA: Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin. Investig. Drugs (2000) 9(12):2923-2934.
32. BLAHETA RA, CINATL J Jr: Anti-tumor mechanisms of valproate: a novel role for an old drug. Med. Res. Rev. (2002) 22(5):492-511.
33. GILLET R, JEANNESSON P, SEFRAOUI H et al.: Piperazine derivatives of butyric acid as differentiating agents in human leukemic cells. Cancer Chemother. Pharmacol. (1998) 41(3):252-255.
34. NUDELMAN A, GNIZI E, KATZ Y et al.: pro-drugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. Eur. J. Med. Chem. (2001) 36(1):63-74.
35. GORE SD, SAMID D, WENG LJ: Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin. Cancer Res. (1997) 3(10):1755-1762.
36. SAMID D, HUDGINS WR, SHACK S, LIU L, PRASANNA P, MYERS CE: Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv. Exp. Med. Biol. (1997) 400A:501-505.
37. JUNG M: Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem. (2001) 8(12):1505-1511.
38. HARRISON LE, WOJCIECHOWICZ DC, BRENNAN MF, PATY PB: Phenylacetate inhibits isoprenoid biosynthesis and suppresses growth of human pancreatic carcinoma. Surgery (1998) 124(3):541-550.
39. SAMID D, WELLS M, GREENE ME, SHEN W, PALMER CN, THIBAULT A: Peroxisome proliferator-activated receptor γ as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity. Clin. Cancer Res. (2000) 6(3):933-941.
40. SANTINI V, GOZZINI A, SCAPPINI B et al.: Induction of apoptosis by monosaccharide butyrate stable derivatives in chronic lymphocytic leukemia cells. Haematologica (1999) 84(10):897-904.
41. SANTINI V, SCAPPINI B, GOZZINI A et al.: Butyrate-stable monosaccharide derivatives induce maturation and apoptosis in human acute myeloid leukaemia cells. Br. J. Haematol. (1998) 101(3):529-538.
42. HEERDT BG, HOUSTON MA, AUGENLICHT LH: Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res. (1994) 54(12):3288-3293.
43. MILOVIC V, TELLER IC, TURCHANOWA L, CASPARY WF, STEIN J: Effect of structural analogues of propionate and butyrate on colon cancer cell growth. Int. J. Colorectal. Dis. (2000) 15(5-6):264-270.
44. GOTTLICHER M, MINUCCI S, ZHU P et al.: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. (2001) 20(24):6969-6978.
45. FONTANA JA, RISHI AK: Classical and novel retinoids: their targets in cancer therapy. Leukemia (2002) 16(4):463-472.
46. BRUSERUD O, GJERTSEN BT, HUANG T. Induction of differentiation and apoptosis - a possible strategy in the treatment of adult acute myelogenous leukemia. Oncologist (2000) 5(6):454-462.
47. TALLMAN MS, NABHAN C, FEUSNER JH, ROWE JM: Acute promyelocytic leukemia: evolving therapeutic strategies. Blood (2002) 99(3):759-767.
48. KAKIZUKA A, MILLER WH Jr, UMESONO K et al.: Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR α with a novel putative transcription factor, PML. Cell (1991) 66(4):663-674.
49. ZHANG C, HAZARIKA P, NI X, WEIDNER DA, DUVIC M: Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin. Cancer Res. (2002) 8(5):1234-1240.
50. WU K, ZHANG Y, XU XC et al.: The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. (2002) 62(22):6376-6380.
51. KHURI FR, RIGAS JR, FIGLIN RA et al.: Multi-institutional Phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (2001) 19(10):2626-2637.
52. WU JM, DIPIETRANTONIO AM, HSIEH TC: Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis (2001) 6(5):377-388.
53. COSTANTINI P, JACOTOT E, DECAUDIN D, KROEMER G: Mitochondrion as a novel target of anticancer chemotherapy. J. Natl. Cancer Inst. (2000) 92(13):1042-1053.
54. DEMETRI GD, FLETCHER CD, MUELLER E et al.: Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. USA (1999) 96(7):3951-3956.
55. MUELLER E, SMITH M, SARRAF P et al.: Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc. Natl. Acad. Sci. USA (2000) 97(20):10990-10995.
56. SARRAF P, MUELLER E, JONES D et al.: Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat. Med. (1998) 4(9):1046-1052.
57. MUELLER E, SARRAF P, TONTONOZ P et al.: Terminal differentiation of human breast cancer through PPARγ. Mol. Cell (1998) 1(3):465-470.
58. ELSTNER E, MULLER C, KOSHIZUKA K et al.: Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA (1998) 95(15 ):8806-8811.
59. KUBOTA T, KOSHIZUKA K, WILLIAMSON EA et al.: Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. (1998) 58(15):3344-3352.
60. SAEZ E, TONTONOZ P, NELSON MC et al.: Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat. Med. (1998)4(9):1058-1061.
61. LEFEBVRE AM, CHEN I, DESREUMAUX P et al.: Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat. Med. (1998) 4(9):1053-1057.
62. HAN S, WADA RK, SIDELL N: Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor γ. Cancer Res. (2001) 61(10 ):3998-4002.
63. BERGE K, TRONSTAD KJ, FLINDT EN et al.: Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways. Carcinogenesis (2001) 22(11):1747-1755.
64. BERGE RK, SKORVE J, TRONSTAD KJ, BERGE K, GUDBRANDSEN OA, GRAV H: Metabolic effects of thia fatty acids. Curr. Opin. Lipidol. (2002) 13(3):295-304.
65. TRONSTAD KJ, BRUSERUD O, BERGE K, BERGE RK: Antiproliferative effects of a non-β-oxidizable fatty acid, tetradecylthioacetic acid, in native human acute myelogenous leukemia blast cultures. Leukemia (2002) 16(11):2292-2301.
66. TRONSTAD K, BERGE K, DYROY E, MADSEN L, BERGE R: Growth reduction in glioma cells after treatment with tetradecylthioacetic acid. Changes in fatty acid metabolism and oxidative status. Biochem. Pharmacol. (2001) 61:639-649.
67. GUPTA RA, DUBOIS RN: Colorecral cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer (2001) 1(1):11-21.
68. DEMPKE W, RIE C, GROTHEY A, SCHMOLL HJ: Cyclooxygenase-2: a novel target for cancer chemotherapy? J. Cancer Res. Clin. Oncol. (2001) 127(7):411-417.
69. SHARMA RA: Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer. QJM (2002) 95(5):267-273.
70. OTA S, BAMBA H, KATO A, KAWAMOTO C, YOSHIDA Y, FUJIWARA K: Review article: COX-2, prostanoids and colon cancer. Aliment. Pharmacol. Ther. (2002) 16(Suppl. 2):102-106.
71. PRESCOTT SM, FITZPATRICK FA. Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta (2000) 1470(2):M69-M78.
72. RINGBOM T, HUSS U, STENHOLM A et al.: Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J. Nat. Prod. (2001) 64(6):745-749.
73. DIRSCH VM, VOLLMAR AM: Ajoene, a natural product with non-steroidal anti-inflammatory drug (NSAID)-like properties? Biochem. Pharmacol. (2001) 61(5):587-593.
74. LEVINE L: Does the release of arachidonic acid from cells play a role in cancer chemoprevention? FASEB J. (2003) 17(8):800-802.
75. ADJEI AA: Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer Inst. (2001) 93(14):1062-1074.
76. BOS JL: ras oncogenes in human cancer: a review. Cancer Res. (1989) 49(17):4682-4689.
77. PRENDERGAST GC, RANE N: Farnesyltransferase inhibitors: mechanism and applications. Expert Opin. Investig. Drugs (2001) 10(12):2105-2116.
78. ROWINSKY EK, WINDLE JJ, VON HOFF DD: Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol. (1999) 17(11):3631-3652.
79. HALUSKA P, DY GK, ADJEI AA: Farnesyl transferase inhibitors as anticancer agents. Eur. J. Cancer (2002) 38(13):1685-1700.
80. WONG WW, DIMITROULAKOS J, MINDEN MD, PENN LZ: HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia (2002) 16(4):508-519.
81. ASIEDU DK, DEMOZ A, SKORVE J, GRAV HJ, BERGE RK: Acute modulation of rat hepatic lipid metabolism by sulphur-substituted fatty acid analogues. Biochem. Pharmacol. (1995) 49(7):1013-1022.
82. COLLETT ED, DAVIDSON LA, FAN YY, LUPTON JR, CHAPKIN RS: n-6 and n-3 polyunsaturated fatty acids differentially modulate oncogenic Ras activation in colonocytes. Am. J. Physiol. Cell Physiol. (2001) 280(5):C1066-C1075.
83. KROEMER G, REED JC: Mitochondrial control of cell death. Nat. Med. (2000) 6(5):513-519.
84. SKULACHEV VP: Fatty acid circuit as a physiological mechanism of uncoupling of oxidative phosphorylation. FEBS Lett. (1991) 294(3):158-162.
85. WALKER JE, RUNSWICK MJ: The mitochondrial transport protein superfamily. J. Bioenerg. Biomembr. (1993) 25(5):435-446.
86. MCMILLIN JB, DOWHAN W: Cardiolipin and apoptosis. Biochim. Biophys. Acta (2002) 1585(2-3):97-107.
87. JOSHI B, LI L, TAFFE BG et al.: Apoptosis induction by a novel anti-prostate cancer compound, BMD188 (a fatty acid-containing hydroxamic acid), requires the mitochondrial respiratory chain. Cancer Res. (1999) 59(17):4343-4355.
88. PAUMEN MB, ISHIDA Y, HAN H et al.: Direct interaction of the mitochondrial membrane protein carnitine palmitoyltransferase I with Bcl-2. Biochem. Biophys. Res. Commun. (1997) 231(3):523-525.
89. KONG JY, RABKIN SW: Palmitate-induced apoptosis in cardiomyocytes is mediated through alterations in mitochondria: prevention by cyclosporin A. Biochim. Biophys. Acta (2000) 1485(1):45-55.
90. KONG JY, RABKIN SW: Palmitate-induced cardiac apoptosis is mediated through CPT-1 but not influenced by glucose and insulin. Am. J. Physiol. Heart Circ. Physiol. (2002) 282(2):H717-H725.
91. FINSTAD HS, DYRENDAL H, MYHRSTAD MC, HEIMLI H, DREVON CA: Uptake and activation of eicosapentaenoic acid are related to accumulation of triacylglycerol in Ramos cells dying from apoptosis. J. Lipid Res. (2000) 41(4):554-563.
92. TRONSTAD KJ, GJERTSEN BT, KRAKSTAD C et al.: Mitochondrial-targeted fatty acid analogue induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leukemia cells. Chem. Biol. (2003) 10:609-618.
93. MILLER AA, KURSCHEL E, OSIEKA R, SCHMIDT CG: Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur. J. Cancer Clin. Oncol. (1987) 23(9):1283-1287.
94. MITCHELL RB, WAGNER JE, KARP JE et al.: Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am. J. Med. (1988) 85(5):662-667.
95. CARDUCCI MA, GILBERT J, BOWLING MK et al.: A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res. (2001) 7(10):3047-3055.
96. GILBERT J, BAKER SD, BOWLING MK et al.: A Phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res. (2001) 7(8):2292-2300.
97. PATNAIK A, ROWINSKY EK, VILLALONA MA et al.: A Phase I study of pivaloyloxymethyl butyrate, a pro-drug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin. Cancer Res. (2002) 8(7):2142-2148.
98. CONLEY BA, EGORIN MJ, TAIT N et al.: Phase I study of the orally administered butyrate pro-drug, tributyrin, in patients with solid tumors. Clin. Cancer Res. (1998) 4(3):629-634.
99. EDELMAN MJ, BAUER K, KHANWANI S et al.: Clinical and pharmacologic study of tributyrin: an oral butyrate pro-drug. Cancer Chemother. Pharmacol. (2003) 51(5):439-444.
100. WARRELL RP Jr, HE LZ, RICHON V, CALLEJA E, PANDOLFI PP: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. (1998) 90(21):1621-1625.
101. PHIEL CJ, ZHANG F, HUANG EY, GUENTHER MG, LAZAR MA, KLEIN PS: Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. (2001) 276(39):36734-36741.
102. LO COCO F, NERVI C, AVVISATI G, MANDELLI F: Acute promyelocytic leukemia: a curable disease. Leukemia (1998) 12(12):1866-1880.
103. MATTHAY KK, VILLABLANCA JG, SEEGER RC et al.: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. (1999) 341(16):1165-1173.
104. HENNEY JE: From the Food and Drug Administration. JAMA (2000) 283(9):1131.
105. ESTEVA FJ, GLASPY J, BAIDAS S et al.: Multicenter Phase II study of oral bexarotene for patients with metastatic breast cancer. J. Clin. Oncol. (2003) 21(6):999-1006.
106. VERONESI U, DE PALO G, MARUBINI E et al.: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst. (1999) 91(21):1847-1856.
107. TRONSTAD K, BERGE K, FLINDT E, KRISTIANSEN K, BERGE R: Optimization of methods and treatment conditions for studying effects of fatty acids on cell growth. Lipids (2001) 36:305-313.
108. GRAV HJ, TRONSTAD KJ, GUDBRANDSEN OA et al.: Changed energy state and increased mitochondrial β-oxidation rate in liver of rats associated with lowered proton electrochemical potential and stimulated uncoupling protein 2 (UCP-2) expression. Evidence for peroxisome proliferator-activated receptor-α independent induction of UCP-2 expression. J. Biol. Chem. (2003) 278(38):30525-30533.
109. SPECTOR AA, BURNS CP: Biological and therapeutic potential of membrane lipid modification in tumors. Cancer Res. (1987) 47(17):4529-4537.
110. PETERSEN ES, KELLEY EE, MODEST EJ, BURNS CP: Membrane lipid modification and sensitivity of leukemic cells to the thioether lipid analogue BM 41.440. Cancer Res. (1992) 52(22):6263-6269.
111. HARDMAN WE: Omega-3 fatty acids to augment cancer therapy. J. Nutr. (2002) 132(11 Suppl.):S3508-S3512.
112. LOCKWOOD K, MOESGAARD S, HANIOKA T, FOLKERS K: Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol. Aspects Med. (1994) 15(Suppl.):S231-S240.
113. WIGMORE SJ, ROSS JA, FALCONER JS et al.: The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition (1996) 12(1 Suppl.):S27-S30.
114. ANTI M, ARMELAO F, MARRA G et al.: Effects of different doses of fish oil on rectal cell proliferation in patients with sporadic colonic adenomas. Gastroenterology (1994) 107(6):1709-1718.
115. MCILLMURRAY MB, TURKIE W: Controlled trial of γ linolenic acid in Duke's C colorectal cancer. Br. Med. J. (Clin. Res. Ed.) (1987) 294(6582):1260.
116. KARMALI RA: Historical perspective and potential use of n-3 fatty acids in therapy of cancer cachexia. Nutrition (1996) 12(1 Suppl.):S2-S4.
117. DAS UN, PRASAD VV, REDDY DR: Local application of γ-linolenic acid in the treatment of human gliomas. Cancer Lett. (1995) 94(2):147-155.
118. BELURY MA: Inhibition of carcinogenesis by conjugated linoleic acid: potential mechanisms of action. J. Nutr. (2002) 132(10):2995-2998.
119. MILNER JA: A historical perspective on garlic and cancer. J. Nutr. (2001) 131(3s):S1027-S1031.
120. PIZER ES, THUPARI J, HAN WF et al.: Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res. (2000) 60(2):213-218.
121. MAGNARD, C, BACHELIER R, VINCENT A et al.: BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains. Oncogene (2002) 21(44):6729-6739.
122. RUBIN MA, ZHOU M, DHANASEKARAN SM et al.: α-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 287(13):1662-1670.